Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 24:10:1161268.
doi: 10.3389/fmed.2023.1161268. eCollection 2023.

One assay to test them all: Multiplex assays for expansion of respiratory virus surveillance

Affiliations

One assay to test them all: Multiplex assays for expansion of respiratory virus surveillance

Narjis Boukli et al. Front Med (Lausanne). .

Abstract

Molecular multiplex assays (MPAs) for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza and respiratory syncytial virus (RSV) in a single RT-PCR reaction reduce time and increase efficiency to identify multiple pathogens with overlapping clinical presentation but different treatments or public health implications. Clinical performance of XpertXpress® SARS-CoV-2/Flu/RSV (Cepheid, GX), TaqPath™ COVID-19, FluA/B, RSV Combo kit (Thermo Fisher Scientific, TP), and PowerChek™ SARS-CoV-2/Influenza A&B/RSV Multiplex RT-PCR kit II (KogeneBiotech, PC) was compared to individual Standards of Care (SoC). Thirteen isolates of SARS-CoV-2, human seasonal influenza, and avian influenza served to assess limit of detection (LoD). Then, positive and negative residual nasopharyngeal specimens, collected under public health surveillance and pandemic response served for evaluation. Subsequently, comparison of effectiveness was assessed. The three MPAs confidently detect all lineages of SARS-CoV-2 and influenza viruses. MPA-LoDs vary from 1 to 2 Log10 differences from SoC depending on assay and strain. Clinical evaluation resulted in overall agreement between 97 and 100%, demonstrating a high accuracy to detect all targets. Existing differences in costs, testing burden and implementation constraints influence the choice in primary or community settings. TP, PC and GX, reliably detect SARS-CoV-2, influenza and RSV simultaneously, with reduced time-to-results and simplified workflows. MPAs have the potential to enhance diagnostics, surveillance system, and epidemic response to drive policy on prevention and control of viral respiratory infections.

Keywords: COVID-19; SARS-CoV-2; diagnostic test; influenza; multiplex assay; respiratory syncytial virus; surveillance.

PubMed Disclaimer

Conflict of interest statement

JF, MG, OO, and CU were employed by Thermo Fisher Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of cycle threshold (Ct)-values (median; min-max) in clinical samples according to each RT-PCR assay. Standards of Care (SoC) are displayed in dark orange, Thermofisher TaqPath™ COVID-19, FluA/B, RSV Combo Kit (TP) in light blue, Kogene PowerChek™ SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit II (PC) in light orange, Cephied Xpert® Xpress SARS-CoV-2, Flu, RSV Kit (GX) in grey. Ct values are displayed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory.

Update of

Similar articles

Cited by

References

    1. World Health Organization . WHO the Top 10 Causes of Death. (2020). Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (Accessed August 12, 2022).
    1. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. . Global, regional, and national causes of under-5 mortality in 2000–19: an updated systematic analysis with implications for the sustainable development goals. Lancet Child Adolesc Health. (2022) 6:106–15. doi: 10.1016/S2352-4642(21)00311-4, PMID: - DOI - PMC - PubMed
    1. Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv Respir Dis. (2021) 15:175346662199505. doi: 10.1177/1753466621995050, PMID: - DOI - PMC - PubMed
    1. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. (2007) 167:354–60. doi: 10.1001/archinte.167.4.ioi60207 - DOI - PubMed
    1. Zhang N, Wang L, Deng X, Liang R, Su M, He C, et al. . Recent advances in the detection of respiratory virus infection in humans. J Med Virol. (2020) 92:408–17. doi: 10.1002/jmv.25674, PMID: - DOI - PMC - PubMed